Author ORCID Identifier

0000-0003-3131-7679

Date of Graduation

5-2023

Document Type

Dissertation (PhD)

Program Affiliation

Genetics and Epigenetics

Degree Name

Doctor of Philosophy (PhD)

Advisor/Committee Chair

Guillermina Lozano

Committee Member

Patrick Lin

Committee Member

Michael Andreeff

Committee Member

Nicholas Navin

Committee Member

Richard Behringer

Abstract

Missense mutations in the DNA binding domain of the Trp53 gene are characterized as structural (p53R172H) or contact (p53R245W) mutations based on their effect on the conformation of the protein. These mutations show gain-of-function activities such as increased metastatic incidence as compared to p53 loss, often mediated by their interaction with a repertoire of transcription factors. These interactions are largely context specific. In order to understand the mechanisms by which these mutations drive osteosarcoma progression, we created a mouse model, wherein either the p53 structural mutant p53R172H, or the contact mutant, p53R245W, are expressed specifically in osteoblasts, yielding osteosarcoma tumor development. We observed a significant decrease in survival and increased metastatic incidence in mice expressing p53 mutants as compared to p53-null mice, suggesting gain of function. RNA-sequencing of primary osteosarcomas revealed that tumors expressing these missense mutants had vastly different gene expression profiles as compared to p53-null tumors. Further, p53R172H and p53R245W regulated unique transcriptomes, that affected distinct pathways, through interactions with a unique repertoire of transcription factors. Validation assays showed that p53R245W, but not p53R172H, interacts with KLF15 to drive migration and invasion in osteosarcoma cell lines, and metastases in allo-transplantation models. Additionally, analyses of p53R248W ChIP peaks showed enrichment of KLF15 motifs in human osteoblasts. Taken together, these data suggest that the structural and contact mutants of p53 have unique mechanisms of action.

Keywords

p53, osteosarcoma, KLF15, GEMMs

Share

COinS